About the Endometriosis Market Endometriosis is a common health condition in women where the endometrial tissue, which is found in the lining of the uterus, appears and grows outside the uterine cavity. The endometrial tissue is shed from the body during menstruation. The tissue growing outside the uterine cavity is called endometrial implants. Endometriosis can also occur in the fallopian tubes, ovaries, pelvic cavity, vagina, cervix, and bladder. In rare cases, it has been reported in other parts of the body such as the lungs, brain, and skin. These implants are usually benign in nature. Women of reproductive age are often affected by this condition. Endometriosis often occurs due to retrograde menstruation, where the menstrual blood flows back into the pelvic cavity instead of leaving the body. This then adheres to the surface of the bladder, ovaries, or rectum and continues to grow or thicken over the course of each menstrual cycle. Technavio's analysts forecast the global endometriosis market to grow at a CAGR of 2.05% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global endometriosis market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of approved and off-label branded and generic drugs used for the treatment and prevention of endometriosis and related pain. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period. The market is divided into the following segments based on geography: Americas APAC EMEA Technavio's report, Global Endometriosis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors AbbVie AstraZeneca Bayer HealthCare Pfizer Other prominent vendors Addex Therapeutics Astellas Pharma Debiopharm ElexoPharm Endoceutics Euroscreen Forendo Pharma Isifer Kissei Pharmaceutical Neurocrine Biosciences Nippon Shinyaku ObsEva Orphagen Pharmaceuticals Philogen PregLem Repros Therapeutics Roivant Sciences SK Chemicals Speciality European Pharma SYNG Pharmaceuticals Takeda United Pharmaceuticals ValiPharma Market driver Increased adoption of OCPs For a full, detailed list, view our report Market challenge Surgeries as primary treatment option For a full, detailed list, view our report Market trend Increased focus on intrauterine devices (IUDs) For a full, detailed list, view our report Key questions answered in this report What will the market size be in 2020 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary Highlights PART 02: Scope of the report Market overview Top-vendor offerings PART 03: Market research methodology Research methodology Economic indicators PART 04: Introduction Key market highlights Endometriosis: An overview PART 05: Pipeline analysis Pipeline molecules based on their mechanism PART 06: Key buying criteria for endometriosis drugs PART 07: Market landscape Market overview Five forces analysis PART 08: Market segmentation by type of therapy Hormone therapy Market size and forecast Pain medications Market size and forecast PART 09: Market segmentation by ROA Oral Parenteral Intrauterine systems Nasal spray PART 10: Geographical segmentation Global endometriosis drugs market by geography 2015-2020 Endometriosis drugs market in Americas Endometriosis drugs market in EMEA Endometriosis drugs market in APAC PART 11: Market drivers Recurrence of endometriosis Increased adoption on OCPs Ineffective existing therapies leading to high unmet need PART 12: Impact of drivers PART 13: Market challenges Poor compliance rates leading to high dropouts Surgeries as primary treatment option Unavailability of proper diagnostic tools PART 14: Impact of drivers and challenges PART 15: Market trends Replacement of GnRH agonists by GnRH antagonists Increased focus on IUDs Development of novel targets for treatment PART 16: Vendor landscape Competitive scenario Key news Major upcoming vendors PART 17: Key vendor analysis AbbVie AstraZeneca Bayer HealthCare Pfizer Other prominent vendors PART 18: Appendix List of abbreviations PART 19: Explore Technavio List of Exhibits
Exhibit 01: Product offerings Exhibit 02: Pipeline portfolio: Global endometriosis drugs market Exhibit 03: Segmentation of pipeline molecules in different stages of development Exhibit 04: Segmentation of pipeline molecules based on their mechanism of action Exhibit 05: Impact of GnRH antagonists on global endometriosis market Exhibit 06: Competitive assessment of marketed and late-stage pipeline molecules Exhibit 07: Key buying criteria for endometriosis drugs Exhibit 08: Global endometriosis market snapshot: Developed and emerging markets 2015 Exhibit 09: Global endometriosis drugs market 2015-2020 ($ billions) Exhibit 10: Opportunity analysis: Global endometriosis drugs market Exhibit 11: Five forces analysis Exhibit 12: Segmentation of global endometriosis drugs market by type of therapy Exhibit 13: Global endometriosis market segmentation by type of therapy 2015 Exhibit 14: Hormone therapies market for endometriosis 2015-2020 ($ billions) Exhibit 15: Pain medications market for endometriosis 2015-2020 ($ millions) Exhibit 16: Global endometriosis market by type of therapy 2015-2020 Exhibit 17: Global endometriosis drugs market by geography 2015-2020 Exhibit 18: Segmentation of global endometriosis drugs market by geography 2015 and 2020 Exhibit 19: Segmentation of global endometriosis drugs market by geography 2015-2020 ($ millions) Exhibit 20: Global endometriosis market by geography 2015-2020 Exhibit 21: Endometriosis drugs market in Americas 2015-2020 ($ millions) Exhibit 22: Endometriosis prevalence in EMEA Exhibit 23: Endometriosis drugs market in EMEA 2015-2020 ($ millions) Exhibit 24: Endometriosis drugs market in APAC 2015-2020 ($ millions) Exhibit 25: Impact of drivers Exhibit 26: Impact of drivers and challenges Exhibit 27: Market share of top vendors in global endometriosis drugs market 2015 Exhibit 28: Geographical presence of major vendors in global endometriosis market Exhibit 29: Competitive scenario of vendors in global endometriosis market 2015-2020 Exhibit 30: Major upcoming vendors in global endometriosis market Exhibit 31: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions) Exhibit 32: AbbVie: Geographical segmentation of Lupron by revenue 2015 Exhibit 33: AbbVie: Metrics analysis Exhibit 34: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions) Exhibit 35: AstraZeneca: Geographic segmentation of Zoladex 2015 Exhibit 36: AstraZeneca: Metrics analysis Exhibit 37: Bayer: YoY revenue and growth rate of Mirena 2013-2015 ($ billions) Exhibit 38: Bayer HealthCare: Metrics analysis Exhibit 39: Pfizer: YoY revenue and growth rate of Depo-Provera 2013-2015 ($ millions) Exhibit 40: Pfizer: Metrics analysis
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.